SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that the U.S. Food and Drug Administration .
Share:
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ( Company ) announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19. The group plans on submitting the publication to a peer review journal.
Dr. Chien-Te Kent Tseng, Professor of the Department of Microbiology and Immunology and Director of GNL s SARS/MERS/COVID-19 Laboratory at UTMB, commented on these results: In our hamster COVID-19 model, pulmonary inflammation with cellular infiltrates and hemorrhage (mild-to-moderate) is triggered by SARS-CoV-2 infection. Treatment with T